Emilio A Emini

6689761, Feb 10, 2004

Feb 1, 1995

08/382113

Jeffrey A. Chodakewitz - Gwynedd Valley PA
Emilio A. Emini - Paoli PA

Merck Co., Inc. - Rahway NJ

A61K 3170

514 49, 514 46, 514 50, 514255

The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

6733993, May 11, 2004

Sep 14, 2001

09/952060

Emilio A. Emini - Wayne PA
Rima Youil - North Wales PA
Andrew J. Bett - Landsdale PA
Ling Chen - Blue Bell PA
David C. Kaslow - Bryn Mawr PA
John W. Shiver - Doylestown PA
Timothy J. Toner - Marlton NJ
Danilo R. Casimiro - Harleysville PA

Merck Co., Inc. - Rahway NJ

C12P 2106

435 691, 435 5, 435 71, 435325, 4353391, 53038835, 536 231, 4241991, 4242081

First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

6787351, Sep 7, 2004

Mar 27, 2001

09/818443

Ling Chen - Blue Bell PA
John W. Shiver - Doylestown PA
Andrew J. Bett - Lansdale PA
Danilo R. Casimiro - Harleysville PA
Michael J. Caulfield - Fort Washington PA
Michael A. Chastain - Glenside PA
Emilio A. Emini - Strafford PA

Merck Co., Inc. - Rahway NJ

C12N 1574

4353201, 435 691, 435 692, 424 932

An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.

7598362, Oct 6, 2009

Oct 10, 2002

10/492178

Emilio A. Emini - Wayne PA, US
David C. Kaslow - Rancho Santa Fe CA, US
Andrew J. Bett - Lansdale PA, US
John W. Shiver - Chalfont PA, US
Alfredo Nicosia - Rome, IT
Armin Lahm - Rome, IT
Alessandra Luzzago - Rome, IT
Riccardo Cortese - Rome, IT
Stefano Colloca - Rome, IT

Merck & Co., Inc. - Rahway NJ
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.p.A. - Rome

C07H 21/04
C12N 7/00

536 231, 536 234, 4242181

The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.

8142794, Mar 27, 2012

Mar 3, 2009

12/396747

Emilio A. Emini - Wayne PA, US
David C. Kaslow - Rancho Santa Fe CA, US
Andrew J. Bett - Lansdale PA, US
John W. Shiver - Chalfont PA, US
Alfredo Nicosia - Rome, IT
Armin Lahm - Rome, IT
Alessandra Luzzago - Rome, IT
Riccardo Cortese - Rome, IT
Stefano Colloca - Rome, IT

Merck Sharp & Dohme Corp. - Rahway NJ

C12N 7/00
C07H 21/04

4242181, 4241891, 536 231, 536 234

The present invention features Ad6 vectors and a nucleic acid encoding a Met-NS3-NS4A-NS4B-NS5A-NS5B polypeptide containing an inactive NS5B RNA-dependent RNA polymerase region. The nucleic acid is particularly useful as a component of an adenovector or DNA plasmid vaccine providing a broad range of antigens for generating an HCV specific cell mediated immune (CMI) response against HCV.

20030228329, Dec 11, 2003

Jun 13, 2003

10/461030

Ling Chen - Blue Bell PA, US
John Shiver - Doylestown PA, US
Andrew Bett - Lansdale PA, US
Danilo Casimiro - Harleysville PA, US
Michael Caulfield - Fort Washington PA, US
Michael Chastain - Glenside PA, US
Emilio Emini - Strafford PA, US

Merck & Co., Inc. - Rahway NJ

A61K039/12
C12N007/00
C12N015/867
C12N015/861

424/199100, 435/456000, 435/235100

An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.

20040101957, May 27, 2004

Mar 14, 2003

10/380641

Emilio Emini - Wayne PA, US
Rima Youil - North Wales PA, US
Andrew Bett - Lansdale PA, US
Ling Chen - Blue Bell PA, US
David Kaslow - Rancho Santa Fe CA, US
John Shiver - Chalfont PA, US
Timothy Toner - Marlton NJ, US
Danilo Casimiro - Harleysville PA, US

C12Q001/68
C12P021/06
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

435/320100, 435/069100, 435/006000

First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

20040106194, Jun 3, 2004

Aug 21, 2003

10/645794

Andrew Bett - Lansdale PA, US
Michael Chastain - Erdenheim PA, US
Volker Sandig - Berlin, DE
Emilio Emini - Wayne PA, US
John Shiver - Chalfont PA, US
Danilo Casimiro - Harleysville PA, US
David Kaslow - Rancho Santa Fe CA, US
Manal Morsy - Blue Bell PA, US

C12Q001/68
C12N007/00
C12N007/01
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74

435/320100, 435/235100, 435/006000

Various methods for propagating and rescuing multiple serotypes of replication-defective adenovirus in a single adenoviral E1-complementing cell line are disclosed. Typically, replication-defective adenovirus vectors propagate only in cell lines which express E1 proteins of the same serotype or subgroup as the vector. The disclosed methods offer the ability to propagate vectors derived from multiple adenoviral serotypes in a single production cell line which expresses E1 proteins from a single serotype. Propagation in this manner is accomplished by providing all or a portion of an E4 region in cis within the genome of the replication-defective adenovirus. The added E4 region or portion thereof is cloned from a virus of the same or highly similar serotype as that of the E1 gene product(s) of the complementing cell line. Interaction between the expressed E1 of the cell line and the heterologous E4 of the replication-defective adenoviral vectors enables their propagation and rescue. The invention bypasses a need in the art to customize specific cell lines to the serotype or subgroup of the adenoviral vector being propagated and enables one to easily and rapidly develop alternative adenoviral serotypes as gene delivery vectors for use as vaccines or as a critical component in gene therapy.